The in vitro activity of trospectomycin against 97 clinical isolates of oral pigmented Bacteroides species was compared with the activities of five other antimicrobial agents. At 4 ,ug/mI, more than 90% of isolates were inhibited by trospectomycin. Overall, strains that produced I8-lactamase (n = 41) were more resistant to trospectomycin, penicillin G, cefoxitin, piperacillin, and tetracycline but not to clindamycin. In this study, trospectomycin had excellent in vitro activity against oral pigmented Bacteroides species.
Trospectomycin (61 propylspectinomycin sulfate pentahydrate) is a new aminocylitol antibiotic that is derived from spectinomycin. In comparison to the parent molecule, trospectomycin has an expanded antimicrobial spectrum and enhanced potency (11) . It has excellent in vitro activity against most gram-positive cocci, as well as against Haemophilus influenzae, Haemophilus ducreyi, Neisseria gonorrhoeae (both P-lactamase-positive and -negative strains), Mycoplasma species, and Chlamydia trachomatis (8, 267, 1987) . Its activity against species of the family Enterobacteriaceae is moderate, comparable to that of spectinomycin. In addition, many anaerobic bacteria are susceptible to trospectomycin in vitro. The MIC for 90% of Bacteroides isolates has been reported to be 4.0 pLg/ml (7) . Because of this broad spectrum of activity, trospectomycin might be a useful drug in the treatment of mixed aerobic-anaerobic infections. In particular, infections that derive from the flora of the oropharynx, such as aspiration pneumonia, empyema, and neck space infections, might be amenable to treatment with trospectomycin. Most of the aerobic organisms involved in these infections are susceptible to trospectomycin in vitro; however, the susceptibility of upper respiratory tract anaerobes is not well documented. Pigmented Bacteroides species are among the most commonly isolated and most antibiotic resistant of the anaerobes associated with these types of infections (3, 4) . The present study was undertaken to determine the in vitro activity of trospectomycin against strains of oral pigmented Bacteroides species and to compare its activity with those of five other antimicrobial agents.
Bacteria used for susceptibility testing were isolated from subgingival plaque samples of outpatients with periodontal disease. After routine processing of the samples, strains were selected on the basis of dark pigmentation Or red fluorescence after 48 to 72 h of anaerobic incubation. All isolates were strictly anaerobic, bile-sensitive, gram-negative bacilli that did not produce catalase (6) . Further identification to species was accomplished using the An-Ident system (Analytab Products, Plainview, N.Y.). MICs were determined by an agar dilution method (10 (2) . It also possesses good activity against experimental subcutaneous abscesses induced with B. fragilis (1) .
Other infections for which trospectomycin might have promise are those due to oropharyngeal flora. These are typically mixed aerobic-anaerobic infections in which pigmented Bacteroides species are prominent pathogens (4). Our results indicate that trospectomycin has excellent in vitro activity against this group of organisms, comparable to the activities of several other antimicrobial agents used to treat infections involving this organism. Since most aerobic respiratory tract pathogens (Streptococcus pneumoniae, H. influenzae, Branhamella species, and streptococci) are also susceptible to trospectomycin, it should be suitable as single-agent therapy. Further investigations on the activity of trospectomycin are warranted.
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